FinTechFunding

Zelira Therapeutics: Launches Zenivol in Australia

  • Zelira Therapeutics (ZLD) has launched its proprietary cannabinoid medicine, Zenivol, in Australia
  • The company has received approval from the Therapeutic Goods Administration’s (TGA) Special Access Scheme to launch the treatment
  • Zenivol is for patients with chronic insomnia and will be available through Zelira’s distribution partner, Health House
  • This announcement follows a successful clinical trial conducted by the University of Western Australia
  • Zelira is on track to launch five new products across global markets in 2020
  • Company shares are up 10 per cent on the market this morning, trading for 6.6 cents per share
Previous article
Saunders International: Awarded $26M defence contract
Next article
Elevations Credit Union: Selects Temenos Infinity
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Visa Launches Validator Node on Tempo Blockchain, Strengthening Payments Infrastructure

New validator node aims to boost transaction efficiency for Visa services.Highlights: Visa launches a new validator node on...
FinTech

Amex Launches Agentic Commerce Development Kit to Strengthen Merchant Services

New toolkit aims to enhance payment solutions for businesses.Highlights: Amex unveils Agentic Commerce Development Kit for merchants.The toolkit...
FinTech

Hokodo B2B Buy Now Pay Later App Shuts Down

The closure impacts small businesses utilizing Hokodo’s service.Highlights: Hokodo, the B2B Buy Now Pay Later app, has ceased...
FinTech

Deutsche Börse Invests in Kraken, Strengthening Crypto Market Position

The investment aims to enhance Kraken's offerings and expand market access.Highlights: Deutsche Börse invests in Kraken to boost...